💊Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China

By FDA, Pharmaceutical

💊Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China

SUMITOMO DAINIPPON PHARMA Co., Ltd.

http://www.ds-pharma.com/ir/news/pdf/ene20180201.pdf

More from tokioX :

  1. 💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
  2. 💊Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy
  3. 💊SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
  4. 💊FDA PHARMA TODAY
  5. 💊FDA PHARMA today
  6. 💊Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries
  7. 💊Dainippon Sumitomo announces the launch of “Seebri ™ Neohaler®” for the treatment of chronic obstructive pulmonary disease (COPD) in the United States  20171020